Literature DB >> 34889383

Optimizing management of sickle cell disease in patients undergoing surgery.

Charity I Oyedeji1, Ian J Welsby1,2.   

Abstract

Individuals with sickle cell disease (SCD) are likely to be referred for surgery at some point in their lifetime due to a high incidence of musculoskeletal and intrabdominal complications such as avascular necrosis and gallbladder disease. Preoperative optimization is a multidisciplinary process that involves a hematologist with SCD expertise, an anesthesiologist, and the surgical team. The type and risk classification of the surgery, disease severity, medications, baseline hemoglobin, transfusion history, and history of prior surgical complications are often documented. Clinicians should consider perioperative risk assessment that includes determining the patient's functional status and cardiovascular risk and screening for obstructive sleep apnea. Many patients will require preoperative transfusion to reduce the risk of postoperative complications such as acute chest syndrome and vaso-occlusive pain crises. The hematologist should consider the patient's preoperative transfusion requirements and ensure that the surgical team has an appropriate plan for postoperative observation and management. This often includes follow-up laboratory studies, a postoperative pain management plan, and venous thromboembolism prophylaxis. The transfusion plan should be patient-specific and take into account the SCD genotype, baseline hemoglobin, disease severity, risk classification of the surgery, and history of prior surgical complications. In the intraoperative and postoperative period, dehydration, hypothermia, hypotension, hypoxia, and acidosis should be avoided, and incentive spirometry should be utilized to minimize complications such as acute chest syndrome. In this review we discuss preoperative, intraoperative, and postoperative strategies to optimize patients with SCD undergoing surgery.
Copyright © 2021 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2021        PMID: 34889383      PMCID: PMC8791118          DOI: 10.1182/hematology.2021000274

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  35 in total

1.  Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Yngve Falck-Ytter; Charles W Francis; Norman A Johanson; Catherine Curley; Ola E Dahl; Sam Schulman; Thomas L Ortel; Stephen G Pauker; Clifford W Colwell
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain.

Authors:  Amanda M Brandow; C Patrick Carroll; Susan Creary; Ronisha Edwards-Elliott; Jeffrey Glassberg; Robert W Hurley; Abdullah Kutlar; Mohamed Seisa; Jennifer Stinson; John J Strouse; Fouza Yusuf; William Zempsky; Eddy Lang
Journal:  Blood Adv       Date:  2020-06-23

3.  The use of rituximab to prevent severe delayed haemolytic transfusion reaction in immunized patients with sickle cell disease.

Authors:  F Noizat-Pirenne; A Habibi; A Mekontso-Dessap; K Razazi; P Chadebech; M Mahevas; B Vingert; P Bierling; F Galactéros; P Bartolucci; M Michel
Journal:  Vox Sang       Date:  2014-12-18       Impact factor: 2.144

4.  Guideline on the peri-operative management of patients with sickle cell disease: Guideline from the Association of Anaesthetists.

Authors:  I Walker; S Trompeter; J Howard; A Williams; R Bell; R Bingham; M Bankes; A Vercueil; S Dalay; D Whitaker; C Elton
Journal:  Anaesthesia       Date:  2021-02-03       Impact factor: 6.955

Review 5.  Surgery in sickle cell disease.

Authors:  Jackie Buck; Sally C Davies
Journal:  Hematol Oncol Clin North Am       Date:  2005-10       Impact factor: 3.722

6.  Pulmonary embolism in sickle cell disease: a case-control study.

Authors:  E M Novelli; C Huynh; M T Gladwin; C G Moore; M V Ragni
Journal:  J Thromb Haemost       Date:  2012-05       Impact factor: 5.824

7.  Extended red blood cell antigen matching for transfusions in sickle cell disease: a review of a 14-year experience from a single center (CME).

Authors:  Michele Lasalle-Williams; Rachelle Nuss; Tuan Le; Laura Cole; Kathy Hassell; James R Murphy; Daniel R Ambruso
Journal:  Transfusion       Date:  2011-02-18       Impact factor: 3.157

8.  Incentive spirometry to prevent acute pulmonary complications in sickle cell diseases.

Authors:  P S Bellet; K A Kalinyak; R Shukla; M J Gelfand; D L Rucknagel
Journal:  N Engl J Med       Date:  1995-09-14       Impact factor: 91.245

9.  Guidance for the treatment and prevention of obstetric-associated venous thromboembolism.

Authors:  Shannon M Bates; Saskia Middeldorp; Marc Rodger; Andra H James; Ian Greer
Journal:  J Thromb Thrombolysis       Date:  2016-01       Impact factor: 2.300

10.  The Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) study: a randomised, controlled, multicentre clinical trial.

Authors:  Jo Howard; Moira Malfroy; Charlotte Llewelyn; Louise Choo; Renate Hodge; Tony Johnson; Shilpi Purohit; David C Rees; Louise Tillyer; Isabeau Walker; Karin Fijnvandraat; Melanie Kirby-Allen; Eldon Spackman; Sally C Davies; Lorna M Williamson
Journal:  Lancet       Date:  2013-01-23       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.